Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) President Craig A. Wheeler sold 5,880 shares of the firm’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $13.68, for a total value of $80,438.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) opened at 14.10 on Friday. The company has a 50-day moving average price of $12.27 and a 200 day moving average price of $11.65. The company’s market capitalization is $972.29 million. Momenta Pharmaceuticals Inc. has a 12-month low of $7.86 and a 12-month high of $18.26.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($0.26) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.03. The company had revenue of $299.14 million for the quarter, compared to the consensus estimate of $25.68 million. Momenta Pharmaceuticals had a negative return on equity of 26.55% and a negative net margin of 93.75%. Momenta Pharmaceuticals’s quarterly revenue was up 2067.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.44) EPS. On average, equities analysts anticipate that Momenta Pharmaceuticals Inc. will post ($1.16) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

A number of brokerages recently commented on MNTA. JPMorgan Chase & Co. dropped their price target on Momenta Pharmaceuticals from $21.00 to $15.00 and set an “overweight” rating for the company in a research note on Friday, August 5th. Barclays PLC reissued a “buy” rating and set a $19.00 price objective on shares of Momenta Pharmaceuticals in a research report on Thursday, November 3rd. Cowen and Company reissued a “hold” rating on shares of Momenta Pharmaceuticals in a research report on Sunday, August 7th. Zacks Investment Research lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 10th. Finally, Maxim Group reissued a “sell” rating and set a $6.00 price objective on shares of Momenta Pharmaceuticals in a research report on Thursday, November 3rd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. Momenta Pharmaceuticals has a consensus rating of “Buy” and an average target price of $16.10.

Institutional investors have recently made changes to their positions in the stock. Pacad Investment Ltd. acquired a new position in shares of Momenta Pharmaceuticals during the second quarter valued at approximately $103,000. Jane Street Group LLC acquired a new position in shares of Momenta Pharmaceuticals during the second quarter valued at approximately $109,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Momenta Pharmaceuticals during the second quarter valued at approximately $109,000. Profund Advisors LLC acquired a new position in shares of Momenta Pharmaceuticals during the third quarter valued at approximately $121,000. Finally, Cornerstone Capital Management Holdings LLC. acquired a new position in shares of Momenta Pharmaceuticals during the third quarter valued at approximately $135,000. 81.62% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/25/craig-a-wheeler-sells-5880-shares-of-momenta-pharmaceuticals-inc-mnta-stock.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).

5 Day Chart for NASDAQ:MNTA

Receive News & Stock Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.